Partnering
Investigator Sponsored Research
Research Collaboration Opportunities
Geron’s research program is proud to provide support for innovative investigator sponsored research (ISR) and collaborative external research. If you have a clinical, real world evidence, translational, or preclinical concept that meets one of our areas of interest and does not conflict with Geron’s current research pipeline, please complete a concept form [linked here] and send to research@geron.com. Proposals may be submitted between June 12, 2025 – August 12, 2025 and December 9, 2025 – February 9, 2026.
Imetelstat Areas of Interest
Lower-Risk Myelodysplastic Syndrome (LR-MDS)
- 1st Line: Monotherapy or combination with therapies that have evidence of monotherapy activity and demonstrated safety profile in LR MDS
- Exploring disease modification potential with earlier treatment
- Adverse event prevention, treatment, and mitigation
- Real world patterns and outcomes of treatment
- Real world evidence on comparative dosing
- Optimal treatment sequencing
- Effects on inflammation, immune response, and/or cytokine modulation
- Additional understanding of the mechanism of action
Higher-Risk Myelodysplastic Syndrome (HR-MDS) / Acute Myeloid Leukemia (AML)
- Secondary AML
- Effect on leukemic stem cells (LSCs) in bone marrow niche
- Exploration of antitumor activity in relevant p53 tumor models
Other MDS/MPN (Myeloproliferative Neoplasms)
- Chronic myelomonocytic leukemia (CMML) and MDS/MPN overlap
- Essential Thrombocythemia (ET) and Polycythemia Vera (PV)
- Mechanistic studies on the role/impact of telomerase inhibition on the JAK pathway
Other Areas of Interest
- Additional understanding of imetelstat mechanism of action
- Hematopoietic stem cell transplant: conditioning regimen or as post-transplant maintenance
- Clonal Cytopenia of Undetermined Significance (CCUS) and VEXAS
- Solid tumors: Exploration of preclinical antitumor activity in hTERT relevant tumor models
- Rational combination therapies in tumor types of interest
Grants, Donations and Sponsorships
Geron may provide funding for educational programs and charitable projects that further medical and scientific knowledge that align with our mission to transform the lives of patients with myeloid hematologic malignancies. Requests for funding must be submitted for review. For more information on our charitable giving and eligibility, including required documentation, please refer to a full overview here.
Educational Programs
We provide funding for CME (Continuing Medical Education) and IME (Independent Medical Education) initiatives aimed at improving care and support for people living with Myelodysplastic Syndromes, Myeloproliferative Neoplasms/Myelofibrosis, and Acute Myeloid Leukemia aligned to prioritized content areas as outlined in our Charitable Giving overview.
For CME inquiries, please submit your request here, for IME inquiries, please submit your request here.
Charitable Giving
Philanthropy is a key component of corporate social responsibility. Geron may provide financial support in response to unsolicited requests for charitable funding intended to benefit patients, caregivers, or patient support communities aligned to our prioritized disease areas and content areas. For inquiries, please submit your request here.
If you are unsure which link to select, this form can help.
Business development
With a seasoned leadership team with world-class expertise spanning research, clinical development, regulatory, manufacturing and commercial experience in hematologic malignancies, Geron is prepared to deliver on our mission to change lives by changing the course of blood cancer and other hematological conditions.
We are interested in accelerating value creation through strategic partnerships that have the potential to bring complementary programs, products, and capabilities that would synergize with our first-in-class telomerase inhibitor and further address unmet medical needs globally.
To contact our Business Development team, please send us an email.